AMB-CHMINACA

AMB-CHMINACA

AMB-CHMINACA is a synthetic cannabinoid that has been used as an active ingredient in synthetic cannabis products. It is a potent agonist of the cannabinoid receptors and has been associated with numerous adverse effects and fatalities.

Chemical Structure and Properties

AMB-CHMINACA, also known as MMB-CHMINACA, is chemically classified as an indazole-based synthetic cannabinoid. Its full chemical name is (S)-methyl 2-(1-(cyclohexylmethyl)-1H-indazole-3-carboxamido)-3-methylbutanoate. The compound is structurally related to other synthetic cannabinoids such as AB-FUBINACA and ADB-CHMINACA.

Pharmacology

AMB-CHMINACA acts as a potent agonist of the CB1 and CB2 cannabinoid receptors. These receptors are part of the endocannabinoid system, which plays a role in regulating various physiological processes including pain sensation, mood, and appetite. The high potency of AMB-CHMINACA at these receptors is responsible for its strong psychoactive effects.

Adverse Effects

The use of AMB-CHMINACA has been linked to a range of adverse effects, including tachycardia, hypertension, nausea, vomiting, agitation, hallucinations, and seizures. In severe cases, it can lead to acute kidney injury, myocardial infarction, and death. The variability in the potency and purity of synthetic cannabinoid products increases the risk of overdose and severe adverse effects.

Legal Status

The legal status of AMB-CHMINACA varies by country. In many jurisdictions, it is classified as a controlled substance due to its potential for abuse and harmful effects. For example, in the United States, it is listed as a Schedule I controlled substance under the Controlled Substances Act.

Detection in Biological Samples

AMB-CHMINACA and its metabolites can be detected in biological samples such as urine and blood using techniques like liquid chromatography-mass spectrometry (LC-MS). These tests are often used in forensic and clinical settings to confirm exposure to the substance.

See Also

• Synthetic cannabinoids
• Cannabinoid receptor
• Endocannabinoid system
• AB-FUBINACA
• ADB-CHMINACA